Five things for pharma marketers to know: Wednesday, June 29, 2016 – Medical Marketing and Media


Medical Marketing and Media
Five things for pharma marketers to know: Wednesday, June 29, 2016
Medical Marketing and Media
1. The FDA approved Gilead Sciences' Epclusa, the first treatment for hepatitis C that spans all genotypes of the virus. The new drug is priced at $74,760 for 12 weeks of treatment. (Bloomberg). 2. An FDA advisory panel voted 12-to-11 that Jardiance, …

and more »

Add a Comment

Your email address will not be published. Required fields are marked *